Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
1 y) S0 \, U2 M/ L7 H C* n8 I, N7 ]5 m- F3 |2 f' e4 O4 U# _& S
+ J6 m; y: W8 E7 k W' b9 I+ @Sub-category:
1 s' M# ]: G6 F1 J D7 R6 cMolecular Targets , c" G* t0 }& }
9 j' x3 u* L% ~' ?
, u- P% A. L6 O: t VCategory:' S0 i* Y4 s- _+ b- p& X6 R' S
Tumor Biology
3 ^+ K3 Q: |) t7 E$ |) m# Q5 ~# f. j) g' u0 G' K' _% s
& u) `" ], a. a: K
Meeting:
7 A9 e6 E/ d Y+ w2011 ASCO Annual Meeting
. _; P* U( S' Y* ]' E% D8 {
' |4 [$ b* o7 S) f7 R' J+ v$ T) M( j& e/ u
Session Type and Session Title:+ c0 P9 x% [9 y& K2 M4 Q/ z
Poster Discussion Session, Tumor Biology C% i4 s5 d# j# T5 T M
& B+ h* B" V6 C& q5 U
* c" w p3 T$ I. e) P7 X7 @
Abstract No:
9 O9 g1 l( I8 J# |: M10517
. b+ y5 v) X6 J- ^( R8 ^
& A( M: {$ ?: A8 l5 p" E( v$ O: c+ d6 `2 V4 j
Citation:
* O# A0 q: L2 O' u% Z- fJ Clin Oncol 29: 2011 (suppl; abstr 10517) - ]2 g: J3 b- Q5 P `# I5 y; ~
6 f. p; }, y9 [$ Y9 \* u) Q9 P. r: L; \# ?
Author(s):
$ g* a: R2 M) n7 U5 {& E4 `0 hJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
4 I0 a' @9 P- G! q
9 s0 G6 b. j% p$ l/ l3 y4 b, C
/ g8 e3 A( F$ e) i, n
/ i+ \8 x/ A# ^4 eAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
. M3 P' s3 ~4 j0 y3 _/ W. `
0 N- P3 S( s9 P( jAbstract Disclosures
/ h9 m: ?) h% x$ O9 ^* u6 z) v+ T) X( ~
Abstract:
4 r7 b8 D7 G0 G) o/ e7 I6 }( s) \; q8 Y% p; J) K/ |% C
6 u5 M2 d$ y( w* X0 d4 @
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
7 P5 r9 j3 V+ j/ G# x
2 L* i& R: |! z 8 p- b! i- ?: V' ?' m; g
|